Diabetic Neuropathy Treatment Market Overview
Diabetic neuropathy is one of the most common causes of neuropathy, a disease which damages the nerves. It is commonly seen in diabetics, with a large section of patient suffering from loss of sensation and weakness. The global diabetic neuropathy treatment market report by Market Research Future (MRFR) has been analyzed by respected research analysts and compiled with the collaboration of industry experts and subject matter experts.
Diabetic Neuropathy Treatment Market research report projects the industry size to grow at CAGR of 5.80% to reach USD 7,719.92 million by 2030.
High prevalence of the disorder is one of the biggest drivers of the market. Treatment of diabetic neuropathy is the second-biggest cause of disability, with close to 30-40% people living with the disorder globally. The large geriatric populace and the sedentary lifestyle are other drivers which can cause the disorder.
The increase noticed in the funding in research and development of novel treatment methods can bode favorably for the market growth. Awareness of new drugs and medications by patients can propel the market demand considerably.
The global diabetic neuropathy treatment market is segmented by disorder, treatment, and end-user.
By disorder, it is segmented into peripheral, autonomic, proximal, and focal. The peripheral segment had the largest market share due to the chances of the disorder affecting women more than men.
By treatment, it is segmented into drugs, transcutaneous electrical nerve stimulation (TENS), and others. Drugs are touted to be the fastest growing segment of the market during the forecast timespan. This can be attributed to the large approval of drugs by regulatory agencies for the treatment of diabetic neuropathy. On the other hand, the TENS segment can experience rapid growth due to being the preferred mode for treatment by adults with the disorder.
By end-user, it is segmented into online pharmacy, retail pharmacy, hospitals & clinics, and others. Hospitals and clinics are expected to retain their position due to the establishments being the primary unit for treatment. Awareness of the disorder combined with availability of treatment and medicines available at these centers can drive the segment growth.
Asia Pacific (APAC), the Americas, Europe, and the Middle East & Africa (MEA) are the regions discussed with respect to the market report.
The Americas is expected to be the largest region for the global diabetic neuropathy treatment market due to its high prevalence. The sophisticated healthcare framework backed by supportive reimbursement packages for patients is expected to propel the market demand by a considerable degree.
The APAC region can display a robust CAGR during the forecast period due to large number of patients affected by the disorder, genetic predisposition, and aging.
Hoffmann-La Roche Ltd, Astellas Pharma Inc, Abbott Laboratories, MEDA Pharma GmBH & Co. KG, Glenmark Pharmaceuticals Limited, Pfizer Inc, GlaxoSmithKline Plc, Johnson & Johnson, Lupin Limited, Eli Lilly and Company, Depomed, Inc., and others are noteworthy participants profiled in the diabetic neuropathy treatment market report. Collaborations and new product launches are strategies to be watched for during the forecast period.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)